TrialLeukemia & lymphoma2016

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.

Soham D Puvvada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.